Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Is there a future for gene therapy?

J M Howell1

  • 1Division of Veterinary and Biomedical Sciences, Murdoch University, Western Australia, Australia.

Neuromuscular Disorders : NMD
|April 30, 1999
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Injection of a recombinant AAV serotype 2 into canine skeletal muscles evokes strong immune responses against transgene products.

Gene therapy·2007
Same author

Lack of toxicity from pediatric beta-blocker exposures.

Human & experimental toxicology·2006
Same author

Evaluation of a short interspersed nucleotide element in the 3' untranslated region of the defective dystrophin gene of dogs with muscular dystrophy.

American journal of veterinary research·2002
Same author

Characterization of the 5'-sequence of the mouse fatty acid amide hydrolase.

Neuroscience letters·2001
Same author

Dystrophin expression in muscle following gene transfer with a fully deleted ("gutted") adenovirus is markedly improved by trans-acting adenoviral gene products.

Human gene therapy·2001
Same author

The spread of transgene expression at the site of gene construct injection.

Muscle & nerve·2001
Same journal

Severe dilated cardiomyopathy in females with dystrophinopathy : a case series of nine patients.

Neuromuscular disorders : NMD·2026
Same journal

A portrait of facioscapulohumeral muscular dystrophy through history: past milestones and future challenges on the road to understanding and treatment.

Neuromuscular disorders : NMD·2026
Same journal

Systematic review of outcome measures in facioscapulohumeral dystrophy (FSHD): validated, usable, and feasible tools for assessing function, performance, and strength.

Neuromuscular disorders : NMD·2026
Same journal

Longitudinal functional trajectories in Duchenne muscular dystrophy: outcome-specific patterns from a registry-based modelling study.

Neuromuscular disorders : NMD·2026
Same journal

HACD1-related congenital myopathy skeletal muscle MRI findings in a Brazilian cohort.

Neuromuscular disorders : NMD·2026
Same journal

Sensory abnormalities and entrapment neuropathies identified by nerve conduction studies in patients with amyotrophic lateral sclerosis.

Neuromuscular disorders : NMD·2026
See all related articles

Gene therapy shows promise for inherited muscle diseases by addressing challenges like delivery and expression duration. Research explores methods to improve somatic gene therapy effectiveness in conditions such as Duchenne muscular dystrophy.

Area of Science:

  • Biomedical Science
  • Molecular Biology
  • Genetics

Background:

  • Gene therapy aims to treat genetic disorders by modifying patient cells.
  • Duchenne muscular dystrophy (DMD) is a severe inherited muscle disease.
  • Early gene therapy trials in humans and animal models have been conducted.

Purpose of the Study:

  • To outline the requirements for successful gene therapy.
  • To review gene therapy trials approved by the NIH (1989-1997).
  • To discuss challenges and potential solutions for somatic gene therapy in inherited muscle diseases.

Main Methods:

  • Review of approved human gene therapy trials.
  • Analysis of gene therapy studies in animal models, particularly the Golden Retriever dog model for DMD.

Related Experiment Videos

  • Exploration of various strategies to overcome delivery, expression, and immune response challenges.

    • Main Results:

    • Gene therapy trials in humans and animals have been initiated.
    • Key challenges include limited expression spread, short duration, and the need for systemic delivery.
    • Potential solutions involve advanced delivery methods, genetic modifications, and immune system modulation.

    Conclusions:

    • Somatic gene therapy holds future potential for treating inherited muscle diseases.
    • Overcoming current limitations is crucial for clinical success.
    • Continued research into novel vectors and therapeutic strategies is essential.